These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25185209)

  • 1. Pregnancy outcomes in patients exposed to interferon beta-1b.
    Romero RS; Lünzmann C; Bugge JP
    J Neurol Neurosurg Psychiatry; 2015 May; 86(5):587-9. PubMed ID: 25185209
    [No Abstract]   [Full Text] [Related]  

  • 2. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
    Blake G; Murphy S
    Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
    [No Abstract]   [Full Text] [Related]  

  • 3. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.
    O'Sullivan SS; Cronin EM; Sweeney BJ; Bourke JF; Fitzgibbon J
    J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1382-3. PubMed ID: 16782776
    [No Abstract]   [Full Text] [Related]  

  • 4. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Niederwieser G
    Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis.
    Rosa DJ; Matias Fde A; Cedrim SD; Machado RF; Sá AA; Silva VC
    An Bras Dermatol; 2011; 86(2):336-8. PubMed ID: 21603818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis.
    Logan-Clubb L; Stacy M
    J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1-inhibitor activity and plasma concentrations in patients with monoclonal gammopathies: implications for treatment with recombinant interferon-beta 1b.
    Schmidt S; Schneider T; Schmidt-Wolf I; Ko Y; Schlegel U; Klockgether T; Hertfelder HJ
    Mult Scler; 2004 Apr; 10(2):243-4. PubMed ID: 15124772
    [No Abstract]   [Full Text] [Related]  

  • 9. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
    Schwid SR; Goodman AD; Mattson DH
    Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 12. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
    Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
    Coyle PK; Sinclair SM; Scheuerle AE; Thorp JM; Albano JD; Rametta MJ
    BMJ Open; 2014 May; 4(5):e004536. PubMed ID: 24821713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
    Durelli L; Oggero A; Verdun E; Isoardo G; Ricci A; Barbero P; Bergamasco B
    J Neurol Sci; 2000 Sep; 178(1):37-41. PubMed ID: 11018247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report.
    Broughton A; Cosyns JP; Jadoul M
    Clin Nephrol; 2011 Nov; 76(5):396-400. PubMed ID: 22000560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].
    Hartung HP; Haas J; Meergans M; Tracik F; Ortler S
    Nervenarzt; 2013 Jun; 84(6):679-704. PubMed ID: 23669866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.